3.36

6.67% -0.24

After Hours: 3.34 -0.02 -0.60%

Cadrenal Therapeutics Inc (CVKD)

Overview News Price History Financials Discussions Forecast

Cadrenal Therapeutics Inc stock is traded at $3.36, with a volume of 64,292. It is down -6.67% in the last 24 hours and down -24.32% over the past month. Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Previous Close:

$3.60

Open:

$3.61

24h Volume:

64,292

Relative Volume:

0.94

Market Cap:

$10.34M

Revenue:

Net Income/Loss:

$-11.89M

P/E Ratio:

-0.5966

EPS:

-5.6317

Net Cash Flow:

$-10.96M

1W Performance:

+11.26%

1M Performance:

-24.32%

6M Performance:

-51.52%

1Y Performance:

-74.11%

1-Day Range:

$3.25

$3.665

1-Week Range:

$2.91

$3.8896

52-Week Range:

$2.55

$14.64

Cadrenal Therapeutics Inc Stock (CVKD) Company Profile

Name

Cadrenal Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

904-300-0701

Address

822 A1A NORTH, PONTE VEDRA

Employee

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

CVKD's Discussions on Twitter

Compare CVKD vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CVKD Cadrenal Therapeutics Inc	3.36	10.28M	0	-11.89M	-10.96M	-5.6317
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-18-23	Initiated	Noble Capital Markets	Outperform

Cadrenal Therapeutics Inc Stock (CVKD) Latest News

Jul 01, 2026

Cadrenal (CVKD) CEO sells 7,400 shares, retains direct and trust stakes - Stock Titan

Jul 01, 2026

Cadrenal Therapeutics CEO sells $22,422 in stock By Investing.com - Investing.com Australia

Jul 01, 2026

Form 4 Cadrenal Therapeutics Inc For: 1 July By Investing.com - Investing.com Canada

Jul 01, 2026

(CVKD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Jul 01, 2026

Cadrenal Therapeutics Raises $3.0 Million in Private Placement of Pre-Funded and Common Warrants - TradingView

Jul 01, 2026

Cadrenal Therapeutics (NASDAQ: CVKD) lines up up to $8.8M via private placement - Stock Titan

Jul 01, 2026

Cadrenal Therapeutics Enters Upto $8.8 Mln Private Placement To Extend Cash Runway; Stock Down - RTTNews

Jul 01, 2026

Jun 30, 2026

Cadrenal Therapeutics raises $3 million in private placement - Investing.com

Jun 30, 2026

Cadrenal Therapeutics raises $3 million in private placement By Investing.com - Investing.com Nigeria

Jun 30, 2026

Cadrenal Therapeutics Announces $3 Million Private Placement with Potential Additional $5.8 Million from Warrants - Quiver Quantitative

Jun 30, 2026

Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewswire

Jun 30, 2026

Jun 29, 2026

Cadrenal Therapeutics Appoints Interim CFO John Sharp Under Master Services Agreement with Lohman & Associates - Minichart

Jun 29, 2026

Cadrenal Therapeutics (NASDAQ: CVKD) names interim CFO and realigns board classes - Stock Titan

Jun 29, 2026

Jun 27, 2026

Cadrenal therapeutics CEO Pham sells $33,919 in stock By Investing.com - Investing.com South Africa

Jun 27, 2026

Price to earnings forward of Cadrenal Therapeutics, Inc. – NASDAQ:CVKD - TradingView

Jun 27, 2026

Price to sales forward of Cadrenal Therapeutics, Inc. – NASDAQ:CVKD - TradingView

Jun 27, 2026

Jun 26, 2026

Cadrenal Therapeutics (CVKD) CEO Quang Pham sells 11,156 shares under 10b5-1 plan - Stock Titan

Jun 26, 2026

Form 4 Cadrenal Therapeutics Inc For: 26 June By Investing.com - Investing.com Canada

Jun 26, 2026

Cadrenal Therapeutics, Inc. Actuals & Estimates (NASDAQ:CVKD) - TradingView

Jun 26, 2026

Jun 25, 2026

CVKD Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 24, 2026

Cadrenal Therapeutics chairman and CEO Pham sells $39,829 in stock. By Investing.com - Investing.com South Africa

Jun 24, 2026

Cadrenal Therapeutics chairman and CEO Pham sells $39,829 in stock. - Investing.com

Jun 24, 2026

Form 4 Cadrenal Therapeutics Inc For: 24 June By Investing.com - Investing.com Australia

Jun 24, 2026

Cadrenal (CVKD) CEO Quang Pham sells 11,444 shares in planned 10b5-1 trades - Stock Titan

Jun 24, 2026

Cadrenal’s HIT drug data selected for presentation at Paris congress - Investing.com UK

Jun 24, 2026

Cadrenal’s HIT drug data selected for presentation at Paris congress By Investing.com - Investing.com South Africa

Jun 24, 2026

Cadrenal’s HIT drug gets late-breaking oral slot at ISTH 2026 - Stock Titan

Jun 24, 2026

Jun 22, 2026